[1] 刘 强,张 庆,全 超.视神经脊髓炎谱系疾病与妊娠[J]. 中国现代神经疾病杂志,2022,22(1):31-37.
[2] Rosito S,Nicchia G P,Palazzo C,et al. Supramolecular aggregation of aquaporin-4 is different in muscle and brain: correlation with tissue susceptibility in neuromyelitis optica[J]. J Cell Mol Med, 2018,22(2):1236-1246.
[3] Steenwinkel F,Dolhain R,Hazes J,et al. Does prednisone use or disease activity in pregnant women with rheumatoid arthritis influence the body composition of their offspring?[J]. ReprodToxicol, 2017,71:118-123.
[4] Ost L,Wettrell G,Björkhem I,et al.Prednisolone excretion in human milk[J].J Pediatr, 1985,106(6):1008-1011.
[5] Colpo A,Marson P,Pavanello F,et al. Therapeutic apheresis during pregnancy: a single center experience[J]. Transfus Apher Sci, 2019,58(5):652-658.
[6] Lipphardt M,Mühlhausen J,Kitze B,et al. Immunoadsorption or plasma exchange in steroid-refractory multiple sclerosis and neuromyelitis optica[J]. J Clin Apher, 2019,34(4):381-391.
[7] Kaplan T B. Management of demyelinating disorders in pregnancy[J]. Neurol Clin, 2019,37(1):17-30.
[8] Achiron A,Kishner I,Dolev M,et al.Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis[J]. J Neurol, 2004,251(9):1133-1137.
[9] Matsumoto Y,Tsuchiya M,Norshalena S,et al. Severe aquaporin 4-IgG-positive neuromyelitis optica with disseminated herpes zoster in a pregnant woman successfully treated with intravenous immunoglobulin[J]. Mult Scler J Exp Tra, 2018,4(1):173-187.
[10] Mahadevan U, Long M D, Kane S V, et al. Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease[J]. Gastroenterology, 2021,160(4):1131-1139.
[11] Polifka J E,Friedman J M.Teratogen update: azathioprine and 6-mercaptopurine[J].Teratology, 2002,65(5):240-261.
[12] Boer N K,Jarbandhan S V,Graaf P, et al. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites[J]. Am J Gastroenterol, 2006,101(6):1390-1392.
[13] Chen B,Wu Q,Ke G,et al.Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder[J]. Sci Rep, 2017,7(1):831.
[14] Bramham K,Chusney G,Lee J,et al.Breastfeeding and tacrolimus: serial monitoring in breast-fed and bottle-fed infants[J]. Clin J Am Soc Nephrol, 2013,8(4):563-567.
[15] Hebert M F,Zheng S,Hays K,et al. Interpreting tacrolimus concentrations during pregnancy and postpartum[J]. Transplantation, 2013,95(7):908-915.
[16] Vaidyanathan A,McKeever K,Anand B,et al. Developmental immunotoxicology assessment of rituximab in cynomolgus monkeys[J]. Toxicol Sci, 2011,119(1):116-125.
[17] Kümpfel T,Thiel S,Meinl I,et al.Anti-CD20 therapies and pregnancy in neuroimmunologicdisorders:a cohort study from Germany[J]. Neurol Neuroimmunol Neuroinflamm, 2021,8(1):e913
[18] Bragnes Y, Boshuizen R, de Vries A, et al. Low level of rituximab in human breast milk in a patient treated during lactation[J]. Rheumatology (Oxford), 2017,56(6):1047-1048.
[19] Cree B, Bennett J L, Kim H J, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum):adouble-blind, randomised placebo-controlled phase 2/3 trial[J].Lancet, 2019,394(10206):1352-1363.
[20] Frampton J E. Inebilizumab: first approval[J]. Drugs, 2020,80(12):1259-1264.
[21] 黄德晖, 吴卫平, 胡学强. 中国视神经脊髓炎谱系疾病诊断与治疗指南(2021版)[J]. 中国神经免疫学和神经病学杂志,2021,28(6):423-436.
[22] Oreja G C, Wray S, Buffels R, et al. Pregnancy outcomes in patients treated with ocrelizumab[J]. J Neurol Sci, 2019,405:311-312.
[23] Maillart E,Renaldo F,Papeix C, et al.Dramatic efficacy of ofatumumab in refractory pediatric-onset AQP4-IgG neuromyelitis optica spectrum disorder[J]. Neurol NeuroimmunolNeuroinflamm, 2020,7(3)
[24] WeberS C, Schaefer C. Pregnancy outcome after tocilizumab therapy in early pregnancy-a case series from the German Embryotox Pharmacovigilance Center[J]. Reprod Toxicol, 2016,60:29-32.
[25] Nakajima K,Watanabe O,Mochizuki M,et al.Pregnancy outcomes after exposure to tocilizumab: a retrospective analysis of 61 patients in Japan[J]. Mod Rheumatol, 2016,26(5):667-671.
[26] Mao D Y, Thiel S, Mills E A, et al. Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations[J]. Nat Rev Neurol, 2020,16(3):154-170.
[27] Sarno L, Tufano A, Maruotti G M, et al.Eculizumab in pregnancy: a narrative overview[J].J Nephrol, 2019,32(1):17-25.
[28] Kelly R J,Höchsmann B,Szer J, et al.Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria[J]. N Engl J Med, 2015,373(11):1032-1039.
[29] Hacohen Y,Rossor T,Mankad K,et al.'Leukodystrophy-like' phenotype in children with myelin oligodendrocyte glycoprotein antibody-associated disease[J]. Dev Med Child Neurol, 2018,60(4):417-423.
[30] Baumann M,Sahin K,Lechner C,et al.Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein[J]. J Neurol Neurosurg Psychiatry, 2015,86(3):265-272.
[31] 黄 鑫,刘建国,王晓风,等.以瘤样脱髓鞘病为首发的视神经脊髓炎二例报道[J].中国神经免疫学和神经病学杂志,2015,22(4):300-302.
[32] Tenembaum S, Yeh E A. Pediatric NMOSD: a review and position statement on approach to work-up and diagnosis[J]. Front Pediatr, 2020,8:339.
[33] Wong Y, Hacohen Y, Armangue T, et al. Paediatric acute disseminated encephalomyelitis followed by optic neuritis: disease course, treatment response and outcome[J]. Eur J Neurol, 2018,25(5):782-786.
[34] 周 季,张 尧,季涛云,等.儿童视神经脊髓炎谱系疾病临床分析[J].中华儿科杂志,2019,57(2):118-124.
[35] Huang W, Wang L, Zhang B, et al. Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: a systematic review and network meta-analysis[J]. Mult Scler Relat Disord, 2019,35:246-252.
[36] Durozard P,Rico A,Boutiere C,et al.Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases[J]. Ann Neurol, 2020,87(2):256-266.
[37] Duchow A, Bellmann S J.Satralizumab in the treatment of neuromyelitis optica spectrum disorder[J]. Neurodegener Dis Manag, 2021,11(1):49-59.
[38] Cai L J,Zhang Q,Zhang Y,et al.Clinical characteristics of very late-onset neuromyelitis optica spectrum disorder[J]. Mult Scler Relat Disord, 2020,46:102515.
[39] Nakahara K,Nakane S,Nagaishi A,et al.Very late onset neuromyelitis optica spectrum disorders[J]. Eur J Neurol, 2021,28(8):2574-2581.
[40] 张晔琼,吕 朴,矫毓娟,等.血浆置换治疗超晚发型视神经脊髓炎谱系疾病的疗效分析[J].中日友好医院学报,2020,34(3):135-139.
[41] 李明月,王建平,周晨光,等.硫唑嘌呤与吗替麦考酚酯治疗晚发型视神经脊髓炎谱系疾病对比研究[J].中国实用神经疾病杂志,2021,24(21):1869-1879.
[42] Ringelstein M,Ayzenberg I,Harmel J,et al. Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder[J]. JAMA Neurol, 2015,72(7):756-763.
[43] Yamamura T,Kleiter I,Fujihara K,et al.Trial of satralizumab in neuromyelitis optica spectrum disorder[J].N Engl J Med, 2019,381(22):2114-2124.
[44] Wingerchuk D M,Fujihara K,Palace J,et al. Long-term safety and efficacy of eculizumab in aquaporin-4 igg-positive NMOSD[J].Ann Neurol, 2021,89(6):1088-1098.
[45] Fragoso Y D, Ruocco H H, Dias R M,et al. Late onset of neuromyelitis optica spectrum disorders[J].Neurol Ther, 2019,8(2):477-482.